Commentary/Editorials

Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies
Mark D. Stewart, Valsamo Anagnostou

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006367; DOI: 10.1136/jitc-2022-006367
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications
Mario Sznol, Naiyer Rizvi

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006346; DOI: 10.1136/jitc-2022-006346
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade
Ming Zheng

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005670; DOI: 10.1136/jitc-2022-005670
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Eleonora Ghisoni, Matteo Morotti, Sara Colomer-Lahiguera, Manuela Eicher, George Coukos, Lionel Trueb, Massimo Di Maio

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e006082; DOI: 10.1136/jitc-2022-006082
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, Delvys Rodriguez-Abreu, Jorge Alatorre-Alexander, Hans J M Smit, Jinming Yu, Konstantinos Syrigos, Elen Höglander, Monika Kaul, Jonathan Tolson, Youyou Hu, Hans Kristian Vollan, Thomas Newsom-Davis

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005581; DOI: 10.1136/jitc-2022-005581
Ensuring equity in the era of HLA-restricted cancer therapeutics
James W Smithy, Amanda Blouin, Lisa C Diamond, Michael Postow

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005600; DOI: 10.1136/jitc-2022-005600
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience
Andrew A Almonte, George Cavic, Teresa Neeman, Anselm Enders, Aude M Fahrer

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005575; DOI: 10.1136/jitc-2022-005575
Ironing out exercise on immuno-oncological outcomes
Janjira Soh, Zi Xiang Lim, Elaine Hsuen Lim, Brian K Kennedy, Jorming Goh

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e002976; DOI: 10.1136/jitc-2021-002976
High antigen density of BCMA: friend or foe to CAR T cells?
Mahmoud R Gaballa, Marcela V Maus

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005822; DOI: 10.1136/jitc-2022-005822
Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
Wen-Yu Zhai, Ze-Rui Zhao, Si Chen, Hui Yu, Yao-Bin Lin, Yi-Zhi Wang, Hao Long

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005160; DOI: 10.1136/jitc-2022-005160

Main menu

Commentary/Editorials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Commentary/Editorials

Pages